Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond
- DOI
- 10.1093/abt/tbag015
- Published
- 2026-04-01
- Container
- Antibody Therapeutics
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/abt/tbag015,
title = {Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond},
author = {Li-Min Wang and Changyong Yang and Simeng Chen and Xing Sun and Yunan Tian and Jieqiong Zhang and Xiaomeng Gao and Dan Li and Wei Zhang and Yali Hu and Jimin Yuan and Qumiao Xu and Xiyang Liu and Long Zhang and Qianqian Yu and Cheng Liao},
year = {2026},
journal = {Antibody Therapeutics},
doi = {10.1093/abt/tbag015},
url = {https://doi.org/10.1093/abt/tbag015}
}RIS
TY - JOUR TI - Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond AU - Li-Min Wang AU - Changyong Yang AU - Simeng Chen AU - Xing Sun AU - Yunan Tian AU - Jieqiong Zhang AU - Xiaomeng Gao AU - Dan Li AU - Wei Zhang AU - Yali Hu AU - Jimin Yuan AU - Qumiao Xu AU - Xiyang Liu AU - Long Zhang AU - Qianqian Yu AU - Cheng Liao PY - 2026 JO - Antibody Therapeutics DO - 10.1093/abt/tbag015 UR - https://doi.org/10.1093/abt/tbag015 ER -
APA
Wang, L., Yang, C., Chen, S., Sun, X., Tian, Y., Zhang, J., Gao, X., Li, D., Zhang, W., Hu, Y., Yuan, J., Xu, Q., Liu, X., Zhang, L., Yu, Q., & Liao, C. (2026). Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag015
Source records
- crossref · retrieved 2026-09-26T20:03:45.477Z